Illumina announced the introduction of its NextSeq™ 550Dx instrument, the company’s second FDA-regulated and CE-IVD marked next-generation sequencing (NGS) system. With the NextSeq 550Dx and also the MiSeqDx, Illumina now has a highly robust diagnostic NGS product portfolio capable of ...
Read More »Development of a RNA-Seq Based Prognostic Signature for Lung Cancer
Precision therapy for lung cancer will require comprehensive genomic testing to identify actionable targets as well as ascertain disease prognosis. RNA-seq is a robust platform that meets these requirements, but microarray-derived prognostic signatures are not optimal for RNA-seq data. Thus, ...
Read More »Innovations Drive Rapid NGS Growth
from R&D Magazine by Tim Studt Modern DNA sequencing began in the mid-1970s following 20 years of development after James Watson and Francis Crick’s 1953 initial determination of the structure of DNA. This sequencing development was made by Frederick ...
Read More »